Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

China's commitment to foster innovation and advance high-standard opening-up has provided global pharmaceutical companies ...

Soliman said consumers could see price increases or shortages of generic drugs in the country. There are some laws that ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...

This photo taken on March 24, 2024 shows the opening ceremony of the China Development Forum 2024 in Beijing, capital of ...

Measles cases in Texas and New Mexico rose to 351 on Friday, the health departments of the states said, an increase of 34 ...

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...